WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the “Company”), said that an internationally renowned Japanese ophthalmologist and corneal researcher, Kazuo Tsubota, MD, PhD, has agreed to perform confirmatory animal efficacy studies of the nanoviricide anti-EKC drug candidate, EKC–Cide™, against EKC (epidemic kerato-conjunctivitis) in Japan. Dr. Tsubota is currently Professor and Chairman of the Department of Ophthalmology at Keio University School of Medicine in Tokyo, Japan.
